HE4 transcription- and splice variants-specific expression in endometrial cancer and correlation with patient survival

International Journal of Molecular Sciences

Volumn 14, Issue 11, 2013, Pages 22655-22677

  Jiang, Shi Wen ^a,b,c   Chen, Haibin ^d   Dowdy, Sean ^b   Fu, Alex ^a   Attewell, John ^b   Kalogera, Eleftheria ^b   Drapkin, Ronny ^e   Podratz, Karl ^b   Broaddus, Russell ^f   Li, Jinping ^a,b,c  

^a MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER   (United States)

^d SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Endometrial cancer; Gene expression; HE4; Splice variants; Transcription

Indexed keywords

BIOLOGICAL MARKER; HE4 PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; BODY WEIGHT; BREAST; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM; ENDOMETRIUM CANCER; EPIDIDYMIS; FEMALE; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HE4 GENE; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; TISSUE SPECIFICITY; TRACHEA;

ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM STAGING; PROTEIN ISOFORMS; PROTEINS; RNA, MESSENGER; SURVIVAL ANALYSIS; TRANSCRIPTION, GENETIC;

EID: 84875537633     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms141122655     Document Type: Article

References (61)

1. SEER Stat Fact Sheets: Endometrial Cancer. Available online: http://seer. cancer. gov/statfacts/html/corp. html (accessed on 14 June 2013).
2. Takeshima, N.; Shimizu, Y.; Umezawa, S.; Hirai, Y.; Chen, J. T.; Fujimoto, I.; Yamauchi, K.; Hasumi, K. Combined assay of serum levels of CA125 and CA19-9 in endometrial carcinoma. Gynecol. Oncol. 1994, 54, 321-326.
3. Yildiz, A.; Yetimalar, H.; Kasap, B.; Aydin, C.; Tatar, S.; Soylu, F.; Yildiz, F. S. Preoperative serum CA 125 level in the prediction of the stage of disease in endometrial carcinoma. Eur. J. Obstet. Gynecol. Reprod. Biol. 2012, 164, 191-195.
4. Sebastianelli, A.; Renaud, M. C.; Gregoire, J.; Roy, M.; Plante, M. Preoperative CA 125 tumour marker in endometrial cancer: Correlation with advanced stage disease. J. Obstet. Gynaecol. Can. 2010, 32, 856-860.
5. Kirchhoff, C.; Osterhoff, C.; Habben, I.; Ivell, R. Cloning and analysis of mRNAs expressed specifically in the human epididymis. Int. J. Androl. 1990, 13, 155-167.
6. Kirchhoff, C.; Habben, I.; Ivell, R.; Krull, N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol. Reprod. 1991, 45, 350-357.
7. Kirchhoff, C. Molecular characterization of epididymal proteins. Rev. Reprod. 1998, 3, 86-95.
8. Bingle, L.; Singleton, V.; Bingle, C. D. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene 2002, 21, 2768-2773.
9. Schummer, M.; Ng, W. V.; Bumgarner, R. E.; Nelson, P. S.; Schummer, B.; Bednarski, D. W.; Hassell, L.; Baldwin, R. L.; Karlan, B. Y.; Hood, L. Comparative hybridization of an array of 21, 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene 1999, 238, 375-385.
10. Anderson, G. L.; McIntosh, M.; Wu, L.; Barnett, M.; Goodman, G.; Thorpe, J. D.; Bergan, L.; Thornquist, M. D.; Scholler, N.; Kim, N.; et al. Assessing lead time of selected ovarian cancer biomarkers: A nested case-control study. J. Natl. Cancer Inst. 2010, 102, 26-38.
11. Drapkin, R.; von Horsten, H. H.; Lin, Y.; Mok, S. C.; Crum, C. P.; Welch, W. R.; Hecht, J. L. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005, 65, 2162-2169.
12. Galgano, M. T.; Hampton, G. M.; Frierson, H. F., Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod. Pathol. 2006, 19, 847-853.
13. Hellstrom, I.; Raycraft, J.; Hayden-Ledbetter, M.; Ledbetter, J. A.; Schummer, M.; McIntosh, M.; Drescher, C.; Urban, N.; Hellstrom, K. E. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003, 63, 3695-3700.
14. Bast, R. C., Jr.; Brewer, M.; Zou, C.; Hernandez, M. A.; Daley, M.; Ozols, R.; Lu, K.; Lu, Z.; Badgwell, D.; Mills, G. B.; et al. Prevention and early detection of ovarian cancer: Mission impossible? Recent Results Cancer Res. 2007, 174, 91-100.
15. Hellstrom, I.; Hellstrom, K. E. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv. Exp. Med. Biol. 2008, 622, 15-21.
16. Li, J.; Dowdy, S.; Tipton, T.; Podratz, K.; Lu, W. G.; Xie, X.; Jiang, S. W. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev. Mol. Diagn. 2009, 9, 555-566.
17. Scholler, N.; Garvik, B.; Quarles, T.; Jiang, S.; Urban, N. Method for generation of in vivo biotinylated recombinant antibodies by yeast mating. J. Immunol. Methods 2006, 317, 132-143.
18. Scholler, N.; Crawford, M.; Sato, A.; Drescher, C. W.; O'Briant, K. C.; Kiviat, N.; Anderson, G. L.; Urban, N. Bead-based ELISA for validation of ovarian cancer early detection markers. Clin. Cancer Res. 2006, 12, 2117-2124.
19. Scholler, N.; Lowe, K. A.; Bergan, L. A.; Kampani, A. V.; Ng, V.; Forrest, R. M.; Thorpe, J. D.; Gross, J. A.; Garvik, B. M.; Drapkin, R.; et al. Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA. Clin. Cancer Res. 2008, 14, 2647-2655.
20. Havrilesky, L. J.; Whitehead, C. M.; Rubatt, J. M.; Cheek, R. L.; Groelke, J.; He, Q.; Malinowski, D. P.; Fischer, T. J.; Berchuck, A. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol. Oncol. 2008, 110, 374-382.
21. Hellstrom, I.; Heagerty, P. J.; Swisher, E. M.; Liu, P.; Jaffar, J.; Agnew, K.; Hellstrom, K. E. Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms. Cancer Lett. 2010, 296, 43-48.
22. Yurkovetsky, Z.; Skates, S.; Lomakin, A.; Nolen, B.; Pulsipher, T.; Modugno, F.; Marks, J.; Godwin, A.; Gorelik, E.; Jacobs, I.; et al. Development of a multimarker assay for early detection of ovarian cancer. J. Clin. Oncol. 2010, 28, 2159-2166.
23. Huhtinen, K.; Suvitie, P.; Hiissa, J.; Junnila, J.; Huvila, J.; Kujari, H.; Setala, M.; Harkki, P.; Jalkanen, J.; Fraser, J.; et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br. J. Cancer 2009, 100, 1315-1319.
24. Moore, R. G.; Brown, A. K.; Miller, M. C.; Badgwell, D.; Lu, Z.; Allard, W. J.; Granai, C. O.; Bast, R. C., Jr.; Lu, K. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol. Oncol. 2008, 110, 196-201.
25. Park, Y.; Kim, Y.; Lee, E. Y.; Lee, J. H.; Kim, H. S. Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int. J. Cancer 2012, 130, 1136-1144.
26. Ruggeri, G.; Bandiera, E.; Zanotti, L.; Belloli, S.; Ravaggi, A.; Romani, C.; Bignotti, E.; Tassi, R. A.; Tognon, G.; Galli, C.; et al. HE4 and epithelial ovarian cancer: Comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin. Chim. Acta 2011, 412, 1447-1453.
27. Shah, C. A.; Lowe, K. A.; Paley, P.; Wallace, E.; Anderson, G. L.; McIntosh, M. W.; Andersen, M. R.; Scholler, N.; Bergan, L. A.; Thorpe, J. D.; et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol. Biomark. Prev. 2009, 18, 1365-1372.
28. Anastasi, E.; Granato, T.; Marchei, G. G.; Viggiani, V.; Colaprisca, B.; Comploj, S.; Reale, M. G.; Frati, L.; Midulla, C. Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women. Tumour. Biol. 2010, 31, 411-415.
29. Moore, R. G.; Brown, A. K.; Miller, M. C.; Skates, S.; Allard, W. J.; Verch, T.; Steinhoff, M.; Messerlian, G.; DiSilvestro, P.; Granai, C. O.; et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol. Oncol. 2008, 108, 402-408.
30. Bignotti, E.; Ragnoli, M.; Zanotti, L.; Calza, S.; Falchetti, M.; Lonardi, S.; Bergamelli, S.; Bandiera, E.; Tassi, R. A.; Romani, C.; et al. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br. J. Cancer 2011, 104, 1418-1425.
31. Lowe, K. A.; Shah, C.; Wallace, E.; Anderson, G.; Paley, P.; McIntosh, M.; Andersen, M. R.; Scholler, N.; Bergan, L.; Thorpe, J.; et al. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol. Biomark. Prev. 2008, 17, 2480-2487.
32. Montagnana, M.; Lippi, G.; Ruzzenente, O.; Bresciani, V.; Danese, E.; Scevarolli, S.; Salvagno, G. L.; Giudici, S.; Franchi, M.; Guidi, G. C. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J. Clin. Lab Anal. 2009, 23, 331-335.
33. Moore, R. G.; McMeekin, D. S.; Brown, A. K.; DiSilvestro, P.; Miller, M. C.; Allard, W. J.; Gajewski, W.; Kurman, R.; Bast, R. C., Jr.; Skates, S. J. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol. Oncol. 2009, 112, 40-46.
34. Jacob, F.; Meier, M.; Caduff, R.; Goldstein, D.; Pochechueva, T.; Hacker, N.; Fink, D.; Heinzelmann-Schwarz, V. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol. Oncol. 2011, 121, 487-491.
35. Montagnana, M.; Danese, E.; Ruzzenente, O.; Bresciani, V.; Nuzzo, T.; Gelati, M.; Salvagno, G. L.; Franchi, M.; Lippi, G.; Guidi, G. C. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: Is it really useful? Clin. Chem. Lab. Med. 2011, 49, 521-525.
36. Li, J.; Fu, A.; Huang, T. H.; Dowdy, S. C.; Podratz, K. C.; Jiang, S. W. Proteomic Identification of HE4 as a potential molecular marker for endometriod cancer of uterus. J Obstet Gynaecol Can. 2013, in preparation.
37. Genomic Structure of HE4. Available online: http://www. ncbi. nlm. nih. gov/sutils/evv. cgi?taxid= 9606&contig=NT_011362. 10&gene=WFDC2&lid=10406 (accessed on 19 August 2004).
38. Kluger, H. M.; Chelouche Lev, D.; Kluger, Y.; McCarthy, M. M.; Kiriakova, G.; Camp, R. L.; Rimm, D. L.; Price, J. E. Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease. Cancer Res. 2005, 65, 5578-5587.
39. Westin, U.; Nystrom, M.; Ljungcrantz, I.; Eriksson, B.; Ohlsson, K. The presence of elafin, SLPI, IL1-RA and STNFalpha RI in head and neck squamous cell carcinomas and their relation to the degree of tumour differentiation. Mediat. Inflamm. 2002, 11, 7-12.
40. Yoshida, N.; Egami, H.; Yamashita, J.; Takai, E.; Tamori, Y.; Fujino, N.; Kitaoka, M.; Schalkwijk, J.; Ogawa, M. Immunohistochemical expression of SKALP/elafin in squamous cell carcinoma of human lung. Oncol. Rep. 2002, 9, 495-501.
41. Devoogdt, N.; Hassanzadeh Ghassabeh, G.; Zhang, J.; Brys, L.; de Baetselier, P.; Revets, H. Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100, 5778-5782.
42. Richardson, R. T.; Sivashanmugam, P.; Hall, S. H.; Hamil, K. G.; Moore, P. A.; Ruben, S. M.; French, F. S.; O'Rand, M. Cloning and sequencing of human Eppin: A novel family of protease inhibitors expressed in the epididymis and testis. Gene 2001, 270, 93-102.
43. Li, J.; Chen, H.; Mariani, A.; Chen, D.; Klatt, E.; Podratz, K.; Drapkin, R.; Broaddus, R.; Dowdy, S.; Jiang, S. W. HE4 (WFDC2) Promotes Tumor Growth in Endometrial Cancer Cell Lines. Int. J. Mol. Sci. 2013, 14, 6026-6043.
44. Idoji, Y.; Watanabe, Y.; Yamashita, A.; Yamanishi, K.; Nishiguchi, S.; Shimada, K.; Yasunaga, T.; Yamanishi, H. In silico study of whey-acidic-protein domain containing oral protease inhibitors. Int. J. Mol. Med. 2008, 21, 461-468.
45. Kamei, M.; Yamashita, S.; Tokuishi, K.; Hashioto, T.; Moroga, T.; Suehiro, S.; Ono, K.; Miyawaki, M.; Takeno, S.; Yamamoto, S.; et al. HE4 expression can be associated with lymph node metastases and disease-free survival in breast cancer. Anticancer Res. 2010, 30, 4779-4783.
46. Kalogera, E.; Scholler, N.; Powless, C.; Weaver, A.; Drapkin, R.; Li, J.; Jiang, S. W.; Podratz, K.; Urban, N.; Dowdy, S. C. Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol. Oncol. 2012, 124, 270-275.
47. Garcia, J. M.; Garcia, V.; Pena, C.; Dominguez, G.; Silva, J.; Diaz, R.; Espinosa, P.; Citores, M. J.; Collado, M.; Bonilla, F. Extracellular plasma RNA from colon cancer patients is confined in a vesicle-like structure and is mRNA-enriched. RNA 2008, 14, 1424-1432.
48. Skog, J.; Wurdinger, T.; van Rijn, S.; Meijer, D. H.; Gainche, L.; Sena-Esteves, M.; Curry, W. T., Jr.; Carter, B. S.; Krichevsky, A. M.; Breakefield, X. O. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 2008, 10, 1470-1476.
49. Leitzmann, M. F.; Koebnick, C.; Danforth, K. N.; Brinton, L. A.; Moore, S. C.; Hollenbeck, A. R.; Schatzkin, A.; Lacey, J. V., Jr. Body mass index and risk of ovarian cancer. Cancer 2009, 115, 812-822.
50. Parkin, D. M. Cancers of the breast, endometrium and ovary: Geographic correlations. Eur. J. Cancer Clin. Oncol. 1989, 25, 1917-1925.
51. Ben-Arie, A.; Huszar, M.; Ben-Zvi, N.; Smirnov, A.; Altevogt, P.; Fogel, M. The role of L1-CAM immunohistochemial staining in the diagnosis of abdominal-pelvic cancer of uncertain primary site in women. Eur. J. Surg. Oncol. 2008, 34, 795-799.
52. Jiang, S. W.; Li, J.; Podratz, K.; Dowdy, S. Application of DNA methylation biomarkers for endometrial cancer management. Expert Rev. Mol. Diagn. 2008, 8, 607-616.
53. Cricca, M.; Venturoli, S.; Leo, E.; Costa, S.; Musiani, M.; Zerbini, M. Molecular analysis of HPV 16 E6I/E6II spliced mRNAs and correlation with the viral physical state and the grade of the cervical lesion. J. Med. Virol. 2009, 81, 1276-1282.
54. Levanon, K.; Ng, V.; Piao, H. Y.; Zhang, Y.; Chang, M. C.; Roh, M. H.; Kindelberger, D. W.; Hirsch, M. S.; Crum, C. P.; Marto, J. A.; et al. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 2010, 29, 1103-1113.
55. Bolstad, N.; Oijordsbakken, M.; Nustad, K.; Bjerner, J. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour. Biol. 2012, 33, 141-148.
56. Bioinformatics Harvester Program. Available online: http://www. embl. de/services/bioinformatics/(accessed on 26 October 2011).
57. Jin, F.; Dowdy, S. C.; Xiong, Y.; Eberhardt, N. L.; Podratz, K. C.; Jiang, S. W. Up-regulation of DNA methyltransferase 3B expression in endometrial cancers. Gynecol. Oncol. 2005, 96, 531-538.
58. Primer3 tool. Available online: http://biotools. umassmed. edu/bioapps/primer3_www. cgi (accessed on 14 January 2006).
59. Li, J.; Wang, E.; Rinaldo, F.; Datta, K. Upregulation of VEGF-C by androgen depletion: The involvement of IGF-IR-FOXO pathway. Oncogene 2005, 24, 5510-5520.
60. Rinaldo, F.; Li, J.; Wang, E.; Muders, M.; Datta, K. RalA regulates vascular endothelial growth factor-C (VEGF-C) synthesis in prostate cancer cells during androgen ablation. Oncogene 2007, 26, 1731-1738.
61. Zhang, H.; Muders, M. H.; Li, J.; Rinaldo, F.; Tindall, D. J.; Datta, K. Loss of NKX3. 1 favors vascular endothelial growth factor-C expression in prostate cancer. Cancer Res. 2008, 68, 8770-8778.